A phase 1 study of KOS-862 (Epothilone D) co-administered with carboplatin (Paraplatin(R)) in patients with advanced solid tumors.
- Published in:
- 2012
- By:
- Publication type:
- Journal Article
Works matching IS 01676997 AND DT 2012 AND VI 30 AND IP 4
Results: 70
1
2
A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-(XL)
- Published in:
- 2012
- By:
- Publication type:
- Journal Article
3
A phase 2 study of oral MKC-1, an inhibitor of importin-[beta], tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer.
- Published in:
- 2012
- By:
- Publication type:
- Journal Article
4
Figitumumab combined with carboplatin and paclitaxel in treatment-naïve Japanese patients with advanced non-small cell lung cancer.
- Published in:
- 2012
- By:
- Publication type:
- Journal Article
5
Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152)
- Published in:
- 2012
- By:
- Publication type:
- Journal Article
6
Intrathecal liposomal cytarabine (lipoCIT) administration in patients with leukemic or lymphomatous meningitis : Efficacy and long-term safety in a single institution.
- Published in:
- 2012
- By:
- Publication type:
- Journal Article
7
Salinomycin, a p-glycoprotein inhibitor, sensitizes radiation-treated cancer cells by increasing DNA damage and inducing G2 arrest.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 4, p. 1311, doi. 10.1007/s10637-011-9685-6
- By:
- Publication type:
- Article
8
Intrathecal liposomal cytarabine (lipoCIT) administration in patients with leukemic or lymphomatous meningitis.
- Published in:
- 2012
- By:
- Publication type:
- Report
9
Changes in imatinib plasma trough level during long-term treatment of patients with advanced gastrointestinal stromal tumors: correlation between changes in covariates and imatinib exposure.
- Published in:
- 2012
- By:
- Publication type:
- Report
10
Synthesis and cytotoxic activities of some 2-Arylnaphtho[2,3- d]oxazole-4,9-dione derivatives on androgen-dependent (LNCaP) and androgen-independent (PC3) human prostate cancer cell lines.
- Published in:
- 2012
- By:
- Publication type:
- Report
11
The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 4, p. 1773, doi. 10.1007/s10637-011-9652-2
- By:
- Publication type:
- Article
12
Synergetic effects of DNA demethylation and histone deacetylase inhibition in primary rat hepatocytes.
- Published in:
- 2012
- By:
- Publication type:
- Report
13
Quaternary ammonium-melphalan conjugate for anticancer therapy of chondrosarcoma: in vitro and in vivo preclinical studies.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 4, p. 1782, doi. 10.1007/s10637-011-9663-z
- By:
- Publication type:
- Article
14
First-line metronomic chemotherapy in a metastatic model of spontaneous canine tumours: a pilot study.
- Published in:
- 2012
- By:
- Publication type:
- Report
15
Caffeic Acid Phenethyl Ester (CAPE) derived from propolis, a honeybee product, inhibits growth of breast cancer stem cells.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 4, p. 1279, doi. 10.1007/s10637-011-9667-8
- By:
- Publication type:
- Article
16
Hydrogen sulfide down-regulates the expression and release of osteoprotegerin (OPG) by vascular endothelial cells.
- Published in:
- 2012
- By:
- Publication type:
- Report
17
The redox antimalarial dihydroartemisinin targets human metastatic melanoma cells but not primary melanocytes with induction of NOXA-dependent apoptosis.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 4, p. 1289, doi. 10.1007/s10637-011-9676-7
- By:
- Publication type:
- Article
18
Cytotoxic effect of menadione and sodium orthovanadate in combination on human glioma cells.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 4, p. 1302, doi. 10.1007/s10637-011-9680-y
- By:
- Publication type:
- Article
19
Effects of the novel DNA dependent protein kinase inhibitor, IC486241, on the DNA damage response to doxorubicin and cisplatin in breast cancer cells.
- Published in:
- 2012
- By:
- Publication type:
- Report
20
A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 4, p. 1501, doi. 10.1007/s10637-011-9683-8
- By:
- Publication type:
- Article
21
Antiangiogenic treatments and mechanisms of action in renal cell carcinoma.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 4, p. 1791, doi. 10.1007/s10637-011-9677-6
- By:
- Publication type:
- Article
22
Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 4, p. 1493, doi. 10.1007/s10637-011-9682-9
- By:
- Publication type:
- Article
23
Combination therapy with the albumin-binding prodrug of doxorubicin (INNO-206) and doxorubicin achieves complete remissions and improves tolerability in an ovarian A2780 xenograft model.
- Published in:
- 2012
- By:
- Publication type:
- Report
24
Cytotoxicity of the new antimetabolite-bisphosphonate (5-FdU-alendronate) in comparison to standard therapeutics on breast and ovarian cancer cell lines in the ATP tumor chemosensitivity assay.
- Published in:
- 2012
- By:
- Publication type:
- Report
25
Phase I results from a two-part Phase I/II study of cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 4, p. 1511, doi. 10.1007/s10637-011-9693-6
- By:
- Publication type:
- Article
26
Safety of bevacizumab 7.5 mg/kg infusion over 10 minutes in NSCLC patients.
- Published in:
- 2012
- By:
- Publication type:
- Report
27
Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152).
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 4, p. 1519, doi. 10.1007/s10637-011-9694-5
- By:
- Publication type:
- Article
28
Nutlin-3 differentially modulates miRNA34a and miRNA181 versus miR26a and miR155 in p53 proficient and p53 deficient B chronic lymphocytic leukemia (B-CLL) samples.
- Published in:
- 2012
- By:
- Publication type:
- Report
29
A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 4, p. 1597, doi. 10.1007/s10637-011-9691-8
- By:
- Publication type:
- Article
30
Enhanced cell cycle perturbation and apoptosis mediate the synergistic effects of ST1926 and ATRA in neuroblastoma preclinical models.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 4, p. 1319, doi. 10.1007/s10637-011-9689-2
- By:
- Publication type:
- Article
31
Reversible posterior leukoencephalopathy syndrome and trastuzumab.
- Published in:
- 2012
- By:
- Publication type:
- Report
32
Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 4, p. 1352, doi. 10.1007/s10637-011-9699-0
- By:
- Publication type:
- Article
33
Development of hemiasterlin derivatives as potential anticancer agents that inhibit tubulin polymerization and synergize with a stilbene tubulin inhibitor.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 4, p. 1379, doi. 10.1007/s10637-011-9702-9
- By:
- Publication type:
- Article
34
Screening of well-established drugs targeting cancer metabolism: reproducibility of the efficacy of a highly effective drug combination in mice.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 4, p. 1331, doi. 10.1007/s10637-011-9692-7
- By:
- Publication type:
- Article
35
Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 4, p. 1607, doi. 10.1007/s10637-011-9703-8
- By:
- Publication type:
- Article
36
Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 4, p. 1531, doi. 10.1007/s10637-011-9697-2
- By:
- Publication type:
- Article
37
The role of CXCR2 chemokine receptors in the oral squamous cell carcinoma.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 4, p. 1371, doi. 10.1007/s10637-011-9701-x
- By:
- Publication type:
- Article
38
Borrelidin, a small molecule nitrile-containing macrolide inhibitor of threonyl-tRNA synthetase, is a potent inducer of apoptosis in acute lymphoblastic leukemia.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 4, p. 1361, doi. 10.1007/s10637-011-9700-y
- By:
- Publication type:
- Article
39
Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 4, p. 1540, doi. 10.1007/s10637-011-9706-5
- By:
- Publication type:
- Article
40
Cell-growth and migration inhibition of human mesothelioma cells induced by 3- O-Methylfunicone from Penicillium pinophilum and cisplatin.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 4, p. 1343, doi. 10.1007/s10637-011-9698-1
- By:
- Publication type:
- Article
41
The HIV reverse transcriptase inhibitor tenofovir induces cell cycle arrest in human cancer cells.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 4, p. 1389, doi. 10.1007/s10637-011-9704-7
- By:
- Publication type:
- Article
42
Sequential therapy with sunitinib and sorafenib in metastatic hepatocellular carcinoma.
- Published in:
- 2012
- By:
- Publication type:
- Report
43
Down-regulation of P-cadherin with PF-03732010 inhibits cell migration and tumor growth in gastric cancer.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 4, p. 1404, doi. 10.1007/s10637-011-9710-9
- By:
- Publication type:
- Article
44
Novel dichlorophenyl urea compounds inhibit proliferation of human leukemia HL-60 cells by inducing cell cycle arrest, differentiation and apoptosis.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 4, p. 1413, doi. 10.1007/s10637-011-9711-8
- By:
- Publication type:
- Article
45
Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 4, p. 1621, doi. 10.1007/s10637-011-9709-2
- By:
- Publication type:
- Article
46
Feasibility and effectiveness of inhaled carboplatin in NSCLC patients.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 4, p. 1628, doi. 10.1007/s10637-011-9714-5
- By:
- Publication type:
- Article
47
SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 4, p. 1646, doi. 10.1007/s10637-011-9719-0
- By:
- Publication type:
- Article
48
Effect of quinolinyl acrylate derivatives on prostate cancer in vitro and in vivo.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 4, p. 1426, doi. 10.1007/s10637-011-9716-3
- By:
- Publication type:
- Article
49
Novel acridine-based agents with topoisomerase II inhibitor activity suppress mesothelioma cell proliferation and induce apoptosis.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 4, p. 1443, doi. 10.1007/s10637-011-9720-7
- By:
- Publication type:
- Article
50
Topical treatment of cutaneous metastases of malignant melanoma using combined imiquimod and 5-fluorouracil.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 4, p. 1641, doi. 10.1007/s10637-011-9717-2
- By:
- Publication type:
- Article